Thank you, Steve.
To give a little bit of my background, I've worked with MDS Nordion for 20 years. I'm a professional engineer and I've worked on the MAPLE project with AECL since its inception.
Medical isotopes are produced when targets are placed in a reactor. When the reactors are operating, neutrons impinge on the reactor and isotopes are created. AECL reported to us every month during the project from 1996 on milestones that were reached during the project. From 2000 to 2008, the MAPLE reactors ran numerous times at various power levels, up to 80% power.
During tests, targets were inserted into the reactor for a number of those tests. When targets are inserted in a reactor and it operates at power, isotopes are created; moly-99 is created. Those targets were not processed, because the processing facility was not yet finished commissioning. So targets are inserted in the reactor, the reactor operates, those targets could be removed and processed, and you would have medical isotopes for sale.
That's the explanation. It's one of the reasons we think that MAPLE has potential.